Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 561 to 570 of 1329 total matches.

Suvorexant (Belsomra) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015  (Issue 1463)
on suvorexant either continued on the active drug or were switched to placebo for 2 months. Patients ...
The FDA has approved suvorexant (Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):29-31 |  Show IntroductionHide Introduction

Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Aug 15, 2016  (Issue 1501)
. In vitro, both sofosbuvir and velpatasvir have potent activity against all major HCV genotypes (1-6 ...
The FDA has approved Epclusa (Gilead), a fixed-dose combination of sofosbuvir (Sovaldi) and velpatasvir, a new direct-acting antiviral agent, for oral treatment of chronic hepatitis C virus (HCV) infection. Epclusa is the first oral combination to be approved for treatment of all six major HCV genotypes.
Med Lett Drugs Ther. 2016 Aug 15;58(1501):107-8 |  Show IntroductionHide Introduction

Cannabidiol (Epidiolex) for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018  (Issue 1559)
to an active metabolite Elimination Primarily in feces Half-life 56-61 hours 183 The Medical Letter ® Vol ...
The FDA has approved cannabidiol oral solution (Epidiolex – Greenwich Biosciences) for treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients ≥2 years old. Cannabidiol (CBD) is a cannabinoid constituent of the marijuana plant (Cannabis sativa). It is the first natural marijuana product to be approved by the FDA for any indication and the first drug to be approved in the US for treatment of Dravet syndrome. Stiripentol (Diacomit), which is not a marijuana product, was also recently approved by the FDA for treatment of Dravet syndrome in...
Med Lett Drugs Ther. 2018 Nov 5;60(1559):182-4 |  Show IntroductionHide Introduction

Stiripentol (Diacomit) for Dravet Syndrome (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 24, 2021  (Issue 1620)
of stiripentol increases serum concentrations of clobazam and its active metabolite, which may potentiate ...
The FDA has approved stiripentol (Diacomit – Biocodex) for treatment of seizures in patients ≥2 years old with Dravet syndrome who are also taking clobazam (Onfi). Stiripentol, which has been available in Europe, Canada, and Japan for many years, is the second drug to be approved in the US for this indication; cannabidiol oral solution (Epidiolex), a purified marijuana product, was the first.
Med Lett Drugs Ther. 2021 Mar 24;63(1620):e1-3 |  Show IntroductionHide Introduction

Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
with methotrexate in patients with active RA despite methotrexate therapy Clinical improvement has occurred ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Med Lett Drugs Ther. 2021 Nov 15;63(1637):e187-9 |  Show IntroductionHide Introduction

Dextromethorphan/Bupropion (Auvelity) for Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
levorphanol; it does not have analgesic activity. Its mechanism of action in treating MDD is unknown ...
The FDA has approved an extended-release fixed-dose combination of dextromethorphan and bupropion (Auvelity – Axsome) for treatment of major depressive disorder (MDD) in adults.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):201-3 |  Show IntroductionHide Introduction

In Brief: Uridine Triacetate (Vistogard) for Fluorouracil Overdose

   
The Medical Letter on Drugs and Therapeutics • Jul 04, 2016  (Issue 1498)
activity of 5-fluorouridine triphosphate, a fluorouracil metabolite, by competing ...
The FDA has approved the pyrimidine analog uridine triacetate (Vistogard – Wellstat Therapeutics) for emergency treatment of a fluorouracil (5-FU) or capecitabine (Xeloda, and generics) overdose or severe toxicity that occurs within 96 hours following administration of one of these drugs. Fluorouracil is a cytotoxic antimetabolite used to treat breast, colorectal, and other cancers; capecitabine is an oral prodrug of fluorouracil.Uridine triacetate, a prodrug, is deacetylated to uridine after oral administration. Excess circulating uridine is converted into uridine triphosphate, which...
Med Lett Drugs Ther. 2016 Jul 4;58(1498):90 |  Show IntroductionHide Introduction

In Brief: Femlyv – An Orally Disintegrating Hormonal Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
blister card contains 24 active (0.02 mg of ethinyl estradiol and 1 mg of norethindrone acetate) and 4 ...
Femlyv (Millicent), an orally disintegrating tablet containing ethinyl estradiol and norethindrone acetate, has been approved by the FDA for prevention of pregnancy in females with a body mass index (BMI) ≤35 kg/m2. It is the first hormonal contraceptive to become available in an orally disintegrating tablet formulation. Traditional oral and chewable tablets containing ethinyl estradiol and norethindrone acetate in a wide range of doses, including those found in Femlyv, have been available in the US for years.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):200   doi:10.58347/tml.2024.1717c |  Show IntroductionHide Introduction

Drugs for HIV Infection

   
Treatment Guidelines from The Medical Letter • Feb 01, 2014  (Issue 138)
with documented resistance to both PIs and other NNRTIs. Etravirine may be active against some HIV-1 strains ...
Antiretroviral therapy is recommended for all HIV-infected patients, both to reduce the risk of disease progression and to prevent transmission of the virus to others. Various guidelines for treatment of HIV infection are available.
Treat Guidel Med Lett. 2014 Feb;12(138):7-16 |  Show IntroductionHide Introduction

Topical Terbinafine for Tinea Infections

   
The Medical Letter on Drugs and Therapeutics • Aug 20, 1993  (Issue 903)
of ergosterol, an essential component of fungal cell membranes. Terbinafine is more active in vitro against ...
Terbinafine 1% cream (Lamisil - Sandoz), an allylamine synthetic antifungal drug chemically related to naftifine (Naftin - Medical Letter, 30:98, 1988), is now available in the USA for topical treatment of tinea pedis, tinea cruris, and tinea corporis infections. An oral formulation is available in Europe and is under investigation here.
Med Lett Drugs Ther. 1993 Aug 20;35(903):76-8 |  Show IntroductionHide Introduction